Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 18/20 | 1.00 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.43 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5276760 | 0.92 | IL2 (0.84) | IL2STIM1ORAI1 | |
| SCHEMBL5275275 | 0.84 | IL2 (0.73) | IL2STIM1ORAI1 | |
| SCHEMBL4762567 | 0.83 | IL2 (0.71) | IL2STIM1ORAI1 | |
| SCHEMBL2817751 | 0.82 | IL2 (0.69) | IL2 | |
| SCHEMBL5047071 | 0.81 | IL2 (0.69) | IL2STIM1ORAI1 | |
| SCHEMBL5316835 | 0.81 | IL2 (0.68) | IL2 | |
| SCHEMBL5554286 | 0.81 | IL2 (0.69) | IL2STIM1ORAI1 | |
| SCHEMBL8263039 | 0.80 | IL2 (0.67) | IL2 | |
| SCHEMBL5271462 | 0.80 | IL2 (0.67) | IL2STIM1ORAI1 | |
| SCHEMBL8261671 | 0.80 | IL2 (0.66) | IL2STIM1ORAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802721-B2 | Thiophene compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-08-12 | — | — | US | claimed |
| EP-1846388-A1 | THIOPHENE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2007-10-24 | — | — | EP | claimed |
| US-20060199845-A1 | Thiophene compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2006-09-07 | — | — | US | claimed |
| WO-2006081389-A1 | THIOPHENE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-03 | — | — | WO | claimed |
| US-8802721-B2 | Thiophene compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802721-B2 | Thiophene compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802721-B2 | Thiophene compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-08-12 | — | — | US | disclosed |
| EP-1846388-A1 | THIOPHENE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2007-10-24 | — | — | EP | disclosed |
| US-20060199845-A1 | Thiophene compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2006-09-07 | — | — | US | disclosed |
| WO-2006081389-A1 | THIOPHENE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-03 | — | — | WO | disclosed |
| WO-2006081389-A1 | THIOPHENE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199845-A1 | Thiophene compounds for inflammation and immune-related uses | CXCR2, TPMT, CXCR1 | IL2 40/4885STIM1 1901/4885ORAI1 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.